All Stories

  1. Systemic Hypertension and Survival in Pulmonary Hypertension
  2. Predictive Power of Pulmonary Artery Stiffness—Right Ventricular Interplay, But Not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension
  3. Pulmonary Veno-occlusive Disease in a Military Pilot: Case Report and Mini-review
  4. Angiotensin Converting Enzyme Inhibition and Mortality in Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH‐COPD)
  5. Sodium restriction and salt replacement in hypertension: a literature review
  6. PVRI ‐ GoDeep —A Global Meta‐Registry at the Crossroads of Heart and Lung
  7. Clinical characteristics of patients with arterial hypertension at the primary care level in Ukraine during the full-scale military conflict and correction (escalation) of therapy with domestic drugs in view of the main international guidelines
  8. Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment
  9. Influence of Potential Pharmacodynamic Drug Interactions in Pharmacotherapy of Coronary Heart Disease with Comorbid Conditions on Treatment Adherence: A Cross-Sectional Study of a Ukrainian Patient Cohort
  10. The Polypill (Acetyl Salicylic Acid, Atorvastatin, and Ramipril) Paradigm Shift in Secondary Prevention: Global Expert Delphi Consensus
  11. 2025 ESC Clinical Consensus Statement on mental health and cardiovascular disease: developed under the auspices of the ESC Clinical Practice Guidelines Committee
  12. Effectiveness of program for active diagnosis of arterial hypertension and other main risk factors for the development of cardiovascular complications in the organized population — “Strong hearts”
  13. Gender-sensitive approach to hypolipidemic therapy: experience from a Ukrainian cohort of patients with coronary heart disease and comorbidities
  14. Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis
  15. Survival Outcomes and Impact of Targeted PAH Therapy in Portopulmonary Hypertension in the PVRI GoDeep Meta‐Registry
  16. Ефективність діагностики й активного виявлення артеріальної гіпертензії та контролю артеріального тиску в організованій популяції за умов воєнного стану в Україні – програма «Сильні серця»
  17. SMAD5 as a novel gene for familial pulmonary arterial hypertension
  18. Association of Phosphodiesterase-5 Inhibitor Treatment With Improved Survival in Pulmonary Hypertension Associated With COPD in the Pulmonary Vascular Research Institute GoDeep Meta-Registry
  19. Клінічні рекомендації з надання фармацевтичної допомоги пацієнтам із підвищеним артеріальним тиском та артеріальною гіпертензією. Методичні рекомендації
  20. Клінічні рекомендації з надання фармацевтичної допомоги пацієнтам із хронічним коронарним синдромом. Методичні рекомендації
  21. Концептуальна модель надання фармацевтичної допомоги пацієнтам на ішемічну хворобу серця з коморбідними станами. Методичні рекомендації
  22. Функція зовнішнього дихання та дифузійна здатність легень у пацієнтів із різними формами легеневої гіпертензії
  23. Comparison of Contemporary Risk Scores in All Groups of Pulmonary Hypertension
  24. Ведення пацієнтів із легеневою гіпертензією в умовах воєнного стану: реалії та проблеми
  25. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension
  26. Blood pressure measurement and assessment of arterial structure and function: an expert group position paper
  27. Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension
  28. Changes in the indicators of hemodynamics and oxygen transport in patients with idiopathic pulmonary arterial hypertension depending on their survival
  29. Cardio-ankle vascular index for predicting cardiovascular morbimortality and determinants for its progression in the prospective advanced approach to arterial stiffness (TRIPLE-A-Stiffness) study
  30. Study of the effect of different drug treatment strategies in patients with hypertension
  31. Реєстр PULSE-COR: взаємозв’язок між еластичністю лівого шлуночка та жорсткістю артерій у пацієнтів з есенціальною артеріальною гіпертензією
  32. When Pulmonary Arterial Hypertension may be Associated with Portal Hypertension: A Case Report of Two Different Hepatic Disorders in One Patient with Pulmonary Hypertension
  33. Chronic thromboembolic pulmonary hypertension: clinical case and problem review
  34. COVID-19 morbidity and its influence on death rate in patients with pulmonary arterial and chronic thromboembolic pulmonary hypertension
  35. “The impact of statins addind to the fixed combination antihypertensive therapy on the arterial stiffness in patients with moderate and severe hypertension"
  36. Effect of cortisol on achieving target blood pressure levels in patients with resistant hypertension and chronic kidney disease
  37. Прихильність до лікування в пацієнтів з резистентною артеріальною гіпертензією
  38. Зміна нормального профілю артеріального тиску за різних чинників стресу в пацієнтів з артеріальною гіпертензією
  39. Prognosis and risk factors for the adverse course of the disease in patients with arterial hypertension and its resistant form
  40. Вплив терапії постійним позитивним тиском у дихальних шляхах на артеріальну жорсткість у пацієнтів з артеріальною гіпертензією і синдромом обструктивного апное сну
  41. The impact of different angiotensin II receptor blockers on the stiffness of the large arteries and effectiveness of therapy
  42. Ventricular Function and Cardio-Ankle Vascular Index in Patients With Pulmonary Artery Hypertension
  43. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
  44. Stress and hypertension: C and H type of hypertension and causes of resistance
  45. Н-тип артеріальної гіпертензії: зв’язок з атеросклерозом сонних артерій
  46. May Measurement Month 2017–2019: an analysis of blood pressure screening results from Ukraine
  47. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
  48. PVRI GoDeep: A meta‐registry merging deep phenotyping data from international PH reference centers
  49. Оцінювання показників спекл-трекінг ехокардіографії в пацієнтів з ідіопатичною легеневою артеріальною гіпертензією
  50. Comparison of the effects of spironolactone and moxonidine as the fourth component of the resistant hypertension therapy on the arterial stiffness
  51. Prognostic value of low ankle-brachial index in patients with resistant hypertension
  52. Діагностичне значення катетеризації правих відділів серця та легеневої артерії у хворих з підозрою на легеневу гіпертензію Частина 2. Інвазивне дослідження показників гемодинаміки та транспорту кисню
  53. Вплив фіксованих комбінацій на артеріальну жорсткість та еректильну функцію в пацієнтів з артеріальною гіпертензією
  54. Abstract P255: Resistance Hypertension And Achievement Of Target Blood Pressure Level By Continuous Positive Airway Pressure Long Therapy In Patients With Obstructive Sleep Apnea
  55. Association between H-type arterial hypertension and vascular stiffness (a pilot study)
  56. CHRONIC KIDNEY DISEASE IN PATIENTS WITH RESISTANCE HYPERTENSION AND ACHIEVEMENT OF TARGET BLOOD PRESSURE
  57. COMPARISON OF SYSTEMIC ARTERIAL STIFFNESS IN PATIENTS WITH NEW DIAGNOSED IDIOPATHIC PULMONARY AND SYSTEMIC ARTERIAL HYPERTENSION
  58. FIXED COMBINATIONS IN ACHIEVEMENT TARGET LEVEL OF BLOOD PRESSURE IN PATIENTS WITH ARTERIAL HYPERTENSION
  59. RED BLOOD CELL DISTRIBUTION IS INDEPENDENTLY ASSOCIATED WITH DAILY DIASTOLIC BP VARIABILITY
  60. RELATIONSHIPS HOMOCYSTEINE AND ARTERIAL STIFFNESS IN PATIENTS WITH H-TYPE ARTERIAL HYPERTENSION
  61. Prognostic Significance of Systemic Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Idiopathic Pulmonary Hypertension
  62. The corona-virus disease 2019 pandemic compromised routine care for hypertension: a survey conducted among excellence centers of the European Society of Hypertension
  63. Роль heart team у діагностиці та лікуванні хронічної тромбоемболічної легеневої гіпертензії
  64. Легенева гіпертензія, асоційована із захворюванням лівих відділів серця (клінічний випадок)
  65. Клінічний випадок легеневої гіпертензії, асоційованої з рідкісною хворобою легень
  66. Діагностичне значення катетеризації правих відділів серця та легеневої артерії у хворих із підозрою на легеневу гіпертензію. Частина 1. Методологія виконання процедури, нозологія захворювань та вазодилататорний тест
  67. Systemic Arterial Stiffness in New Diagnosed Idiopathic Pulmonary Arterial Hypertension Patients
  68. Association between arterial stiffness and obstructive sleep apnea in patients with arterial hypertension and continuous positive airway pressure therapy
  69. Легенева гіпертензія: стан проблеми та аналіз роботи референтного центру (дані першого українського реєстру)
  70. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
  71. Ambulatory blood pressure and arterial stiffness web‐based telemonitoring in patients at cardiovascular risk. First results of the VASOTENS (Vascular health ASsessment Of The hypertENSive patients) Registry
  72. Вплив блокаторів рецепторів ангіотензину II на зміни артеріального тиску при добовому моніторуванні залежно від ранкового або вечірнього прийому
  73. Pulmonary hypertension register in Ukraine
  74. 2018 ESC/ESH Guidelines for the management of arterial hypertension
  75. Influence of fixed-dose combination perindopril/amlodipine on target organ damage in patients with arterial hypertension with and without ischemic heart disease (results of EPHES trial)
  76. A17130 Comparison of factors associated with target organ damage regress on foxed dose combination perindopril/amlodipine in hypertensive patients with and without ischemic heart disease
  77. A11719 pulse-cor registry
  78. May Measurement Month 2017: an analysis of blood pressure screening results worldwide
  79. CORRELATION RELATIONSHIPS AGES, OFFICE BLOOD PRESSURE, EGFR, RENIN, ALDOSTERONE, METANEPHRYLS LEVELS IN PATIENTS WITH RESISTANT HYPERTENSION
  80. FACTORS ASSOCIATED WITH TARGET ORGAN DAMAGE REGRESS ON FIXED DOSE COMBINATION PERINDOPRIL/AMLODIPIN IN HYPERTENSIVE PATIENTS WITH AND WITHOUT ISCHEMIC HEART DISEASE
  81. HOME BP LEVELS AND ARTERIAL STIFFNESS IN PATIENTS WITH MILD TO MODERATE ARTERIAL HYPERTENSION
  82. INFLUENCE OF DIFFERENT CLASSES OF ANTIHYPERTENSIVE DRUGS ON INSULIN RESISTANCE IN PATIENTS WITH MILD AND MODERATE ARTERIAL HYPERTENSION
  83. INFLUENCE OF HYPERURICEMIA ON ELASTIC PROPERTIES OF ARTERIES IN PATIENTS WITH ARTERIAL HYPERTENSION
  84. PULSE-COR REGISTRY
  85. PULSE-COR REGISTRY
  86. Effects of metabolic syndrome on arterial function in different age groups
  87. The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension: a subgroup analysis of the effect of valsartan and its combination with…
  88. The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension…
  89. [PP.04.17] ADDITIONAL FACTORS THAT MAY HELP IN LV DIASTOLIC FUNCTION ASSESSMENT
  90. [PP.04.16] ARTERIAL STIFFNESS, VENTRICLE-ARTERIAL COUPLING AND LV FUNCTION IN PATIENTS WITH MODERATE TO SEVERE AH
  91. [PP.22.13] EVALUATION OF EFFICACY AZILSARTAN MEDOXOMIL ON CENTRAL AORTIC BLOOD PRESSURE AND AMBULATORY BLOOD PRESSURE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION
  92. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial
  93. Effect of Beta - Blockers on Insulin Resistance in Patients with Hypertension and Metabolic Syndrome after 6 Months of Treatment
  94. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves
  95. Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia
  96. The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension — the VICTORY trial
  97. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation
  98. Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry
  99. PS 17-64 ADDITIONAL FACTORS ASSOCIATED WITH DIASTOLIC FUNCTION IN PATIENTS WITH ARTERIAL HYPERTENSION
  100. [PP.03.03] ADDITIONAL FACTORS ASSOCIATED WITH LEFT VENTRICLE DIASTOLIC FUNCTION IMPAIRMENT IN PATIENTS WITH MODERATE HYPERTENSION
  101. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin
  102. [PP.23.22] CORRELATION CENTRAL BLOOD PRESSURE RESPONSE WITH CREATININ, EGFR AND HEART RATE AFTER RENAL DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION IN UKRAINE
  103. PS 11-55 CORRELATION RELATIONSHIP HOMA INDEX WITH BLOOD PRESSURE, HEART RATE AND LIPID IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME WITHOUT DIABETES TREATED DIFFERENT BETA BLOCKERS
  104. [PP.01.07] EFFECTS OF AZILSARTAN MEDOXOMIL ON CENTRAL AORTIC AND AMBULATORY BLOOD PRESSURE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION
  105. PS 17-42 FIXED DOSE COMBINATION PERINDOPRIL/AMLODIPIN AND TARGET ORGAN DAMAGE IN PATIENTS WITH ARTERIAL HPERTENSION AND ISCHEMIC HEART DISEASE
  106. [PP.13.17] GENDER DIFFERENCES IN BLOOD PRESSURE CONTROL IN HYPERTENSIVE PATIENTS
  107. [PP.13.02] IMPACT OF STATINS ON THE PERINDOPRIL/AMLODIPINE ANTIHYPERTENSIVE EFFICACY IN PATIENTS WITH HYPERCHOLESTEROLEMIA
  108. [PP.26.07] IMPACT OF VALSARTAN AND COMBINATION OF VALSARTAN AND HYDROCHLOROTHIAZIDE ON ERECTILE DYSFUNCTION IN PATIENTS WITH MILD TO MODERATE HYPERTENSION
  109. PS 14-35 INFLUENCE OF AZILSARTAN MEDOXOMIL ON CENTRAL AORTIC BLOOD PRESSURE AND AMBULATORY BLOOD PRESSURE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION
  110. [PP.29.24] METABOLIC EFFECTS DIFFERENT BETA BLOCKERS DEPENDS ON PRESENTS INSULIN RESISTANCE IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME
  111. [PP.13.13] ONE MONTH BLOOD PRESSURE LOWERING EFFICACY RESULTS OF A NOVEL FIRST-LINE TREATMENT IN HYPERTENSION
  112. [PP.22.17] THE LEFT VENTRICLE DIASTOLIC FUNCTION PROFILE IN PATIENTS WITH ARTERIAL HYPERTENSION AND MILDLY REDUCED KIDNEY FUNCTION
  113. Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial
  114. Predictors of high central blood pressure in young with isolated systolic hypertension
  115. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events
  116. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48
  117. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
  118. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT
  119. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
  120. Autoantibodies against tyrosyl-tRNA synthetase and its separated domains at essential hypertension
  121. PP.06.19
  122. PP.01.18
  123. PP.07.33
  124. PP.18.03
  125. PP.07.38
  126. PP.20.38
  127. PP.07.36
  128. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
  129. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
  130. Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg/amlodipine 2.5 mg as a first-step treatment in hypertension
  131. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient
  132. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline
  133. Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin
  134. CARDIOVASCULAR MORTALITY IN PATIENTS WITH TYPE 2 DIABETES AND RECENT ACUTE CORONARY SYNDROMES FROM THE EXAMINE TRIAL
  135. Edoxaban versus Warfarin in Patients with Atrial Fibrillation
  136. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
  137. Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial
  138. Diet and Kidney Disease in High-Risk Individuals With Type 2 Diabetes Mellitus
  139. 2013 ESH/ESC Guidelines for the management of arterial hypertension
  140. 2013 ESH/ESC Guidelines for the management of arterial hypertension
  141. Current and future initiatives for vascular health management in clinical practice
  142. Single‐Pill Combination of Telmisartan/Amlodipine in Patients With Severe Hypertension: Results From the TEAMSTA Severe HTN Study
  143. Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination
  144. HOME SELF MEASUREMENT MONITORING OF BLOOD PRESSURE: RELATION TO OFFICE AND AMBULATORY BLOOD PRESSURE MEASUREMENT: PP.14.15
  145. POSSIBILITY OF BLOOD PRESSURE CONTROL BY UKRAINIAN GENERIC DRUGS IN DIABETIC HYPERTENSIVE PATIENTS IN PRIMARY CARE SETTING: RESULTS OF MULTICENTRE OPEN TRIAL: PP.17.128
  146. INFLUENCE DIFFERENT TYPE OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION (AH) AND METABOLIC SYNDROME (MS) ON INSULIN RESISTANCE DEPENDS ON SEX: PP.34.398
  147. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
  148. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
  149. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
  150. Influence of losartan vs amlodipin on pulse wave velocity in patients with mild to moderate arterial hypertension
  151. Regression of left ventricular hypertrophy in patients who agreed to have repeat examination at 5 years after treatment in specialized hypertensive unit
  152. Renal function in patients with renoparenchymal arterial hypertension in dependency from treatment (3 year observation)
  153. CAROTID STRUCTURE AND HEMODYNAMIC, ITS RELATION WITH ARTERIAL BLOOD PRESSURE IN PATIENTS WITH MILD TO MODERATE ARTERIAL HYPERTENSION
  154. DYNAMICS OF STATISTICAL AND EPIDEMIOLOGICAL DATA OF THE PROGRAM FOR ARTERIAL HYPERTENSION PREVENTION AND TREATMENT IN UKRAINE REALIZATION
  155. GENERAL PRACTITIONERS EXPERIENCE OF USING TELMISARTAN IN PATIENTS WITH ARTERIAL HYPERTENSION (RESULTS OF OPEN MULTICENTRAL STUDY IN UKRAINE)
  156. ?Dipper? and ?non-dipper? phenomena and heart rate variability in patients with mild to moderate arterial hypertension
  157. Antihypertensive effectiveness of the valsartan and its influence on morning surge in patients with mild to moderate arterial hypertension
  158. Target organ damage in patients with mild to moderate essential and renoparenchymal arterial hypertension
  159. Systemic arterial compliance in patients with high and low renin essential hypertension
  160. 24-HOUR BLOOD PRESSURE AND HEART RATE VARIABILITY MONITORING DURING TREATMENT BY DIFFERENT LONG-ACTING DIHYDROPYRIDINES (NITRENDIPINE, LACIDIPINE OR NIFEDIPINE)
  161. INFLUENCE OF LOSARTAN AND VALSARTAN ON BLOOD PRESSURE AND HEART RATE VARIABILITY IN MODERATE HYPERTENSION PATIENTS
  162. NEBIVOLOL INDUCED HAEMODYNAMIC CHANGES IN PATIENTS WITH CONGESTIVE HEART FAILURE CAUSED BY RENAL ARTERIAL HYPERTENSION
  163. Influence of long-term losartan monotherapy on regress of myocardial hypertrophy and left ventricular function in renal parenchymal arterial hypertension
  164. The cardiac death and the level of blood pressure in patients with congestive heart failure after progressive angina
  165. <title>Laser blood irradiation effect on electrophysiological characteristics of acute coronary syndrome patients</title>
  166. Carrier capture in quantum well embedded quantum wire structures
  167. Coulomb coupling between two-dimensional and three-dimensional electron-gas layers: Influence on electrical transport
  168. Dielectric formalism for a quasi-one-dimensional electron gas. I. Quantum transport equations
  169. Nonlinear Conductivity of a Degenerate Two‐Dimensional Electron Gas